<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Outcome Measures on Alejandro Caravaca Puchades</title><link>https://www.acpuchades.com/tags/outcome-measures/</link><description>Recent content in Outcome Measures on Alejandro Caravaca Puchades</description><generator>Hugo -- gohugo.io</generator><language>en</language><copyright>© 2026 Alejandro Caravaca Puchades</copyright><lastBuildDate>Mon, 11 May 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://www.acpuchades.com/tags/outcome-measures/index.xml" rel="self" type="application/rss+xml"/><item><title>The ALSFRS-R: what it measures, why we use it, and where it fails</title><link>https://www.acpuchades.com/blog/alsfrs-critical-appraisal-part-ii/</link><pubDate>Mon, 11 May 2026 00:00:00 +0000</pubDate><guid>https://www.acpuchades.com/blog/alsfrs-critical-appraisal-part-ii/</guid><description>A structured tour of the ALSFRS-R: its twelve items across four functional domains, why feasibility and sensitivity to change made it the field&amp;rsquo;s standard outcome measure for twenty-five years, and a frank account of the psychometric limitations that have accumulated against it.</description></item><item><title>What are we actually measuring?</title><link>https://www.acpuchades.com/blog/alsfrs-critical-appraisal-part-i/</link><pubDate>Tue, 05 May 2026 00:00:00 +0000</pubDate><guid>https://www.acpuchades.com/blog/alsfrs-critical-appraisal-part-i/</guid><description>Clinical trials in ALS live or die by their outcome measures. This opening piece of the series frames the measurement problem in neurodegeneration — biological versus functional endpoints — and sets up why the ALSFRS-R became the field&amp;rsquo;s default answer to it.</description></item></channel></rss>